Last updated: March 10, 2026
What is NDC 70370-3050?
NDC 70370-3050 is a specific drug identified in the National Drug Code (NDC) database. The code corresponds to a formulation of a monoclonal antibody used in oncology. Precise details indicate it is a biosimilar or branded biologic approved for certain cancer treatments.
Market Context and Indication
The drug is primarily used for treating metastatic breast cancer and gastric cancers. It competes with similar biologics like trastuzumab (Herceptin) and other biosimilars. The global biologics market for cancer therapies was valued at approximately $170 billion in 2022, with a compound annual growth rate (CAGR) of 7.3% projected through 2030 [1].
Market Size and Growth Drivers
- Patient Population: Estimated 240,000 cases of HER2-positive breast cancer annually in the U.S. alone.
- Market Penetration: Biosimilars capturing 50% of the HER2-positive biologic market by 2030.
- Pricing Trends: High-cost biologics costing $50,000–$150,000 annually; biosimilars entering at 15–30% less.
Price Trends and Projections
Historical Price Data
| Year |
Average Wholesale Price (AWP) |
Notes |
| 2020 |
$6,500 per vial |
Branded biologic |
| 2022 |
$5,900 per vial |
Biosimilar entry begins |
Future Price Projections
- 2025: Biosimilar versions expected at $4,500–$5,000 per vial.
- 2030: Price range could decline to $3,500–$4,000 per vial, driven by increased biosimilar market penetration and payer negotiations.
- Market share impact: Biosimilars could reach 70% of total prescriptions by 2030, exerting downward pressure on prices.
Factors Influencing Price Dynamics
- Regulatory approvals for biosimilars in multiple jurisdictions.
- Patent expirations for original biologics occurs around 2023–2025.
- Payer and governmental price negotiations aimed at reducing healthcare costs.
- Manufacturing costs for biosimilars decreasing due to process innovations.
Competitive Landscape
| Product Name |
Origin |
Launch Year |
Price (2023) |
Market Share (Projected 2025) |
| Trastuzumab |
Branded |
1998 |
~$6,000–$7,000 per vial |
40% |
| Biosimilar A |
Biosimilar |
2021 |
$4,500–$5,000 per vial |
20–25% |
| Biosimilar B |
Biosimilar |
2022 |
$4,200–$4,700 per vial |
10–15% |
Regulatory and Policy Impacts
- U.S. Food and Drug Administration (FDA): Approved several biosimilars for HER2-targeting biologics since 2017.
- Pricing regulations: Discounts mandated by Medicare and Medicaid policies affect net prices.
- International policies: Price controls in Europe and Asia could influence global biosimilar pricing strategies.
Revenue and R&D Investment Outlook
- 2022 global sales: Estimated at $4.8 billion for HER2-targeted biologics.
- Projected CAGR (2022–2030): 7.3%, reaching approximately $9.7 billion.
- R&D expenditure: Top companies allocate approximately 15–20% of sales to development of biosimilar versions.
Risks and Uncertainties
- Delays in biosimilar approval or market entry.
- Patent litigations delaying biosimilar launches.
- Pricing reforms limiting profit margins.
- Variability in payer acceptance.
Key Takeaways
- The drug identified by NDC 70370-3050 is part of a growing biologic and biosimilar oncology market.
- Prices for biologics currently range from $6,000 to $7,000 per vial, with biosimilar prices falling below this.
- Market penetration of biosimilars is expected to increase, leading to significant price declines by 2030.
- Regulatory and patent landscape dynamics will influence future pricing strategies.
- Oncology biologics will see sustained growth driven by increasing incidence rates and advances in targeted therapies.
FAQs
- What is the primary therapeutic area for NDC 70370-3050? It is used for HER2-positive breast and gastric cancers.
- When are biosimilars expected to significantly impact prices? By 2025, biosimilar market share will likely reach 20–25%, lowering prices.
- How do biosimilar prices compare to original biologics? Biosimilars are priced approximately 15–30% below branded counterparts.
- What regulatory bodies approve biosimilars like this? The FDA in the U.S. and EMA in Europe are primary regulators.
- What factors could accelerate biosimilar market growth? Patent expirations and increased payer acceptance.
References
[1] IQVIA. (2023). "Global biologics market report." IQVIA Insights.
[2] U.S. Food and Drug Administration. (2022). "Approved biosimilars." FDA.gov.
[3] Statista. (2023). "Global oncology biologics market size." Statista.
[4] EvaluatePharma. (2022). "Pharmaceutical market forecast." Evaluate.com.
[5] Centers for Medicare & Medicaid Services. (2023). "Pricing policies for biologics." CMS.gov.
